Other studies assessed the prevalence of SGLT2-i treatment and its association with restenosis risk in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease. This evidence concerns the gene SLC5A2 and peripheral arterial disease.